A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (CTMS# 21-0
Lay Description
Category
- IRB Number
- 20210831HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Virginia Diaz
210-562-9149
diazvr@uthscsa.edu
Jaclyn Hung
210-450-5358
hungj@uthscsa.edu
Principal Investigator
Allison C Grimes